17/07/2025
Winlevi® (clascoterone cream 1%) is now in Singapore and Malaysia! We’re proud to introduce this novel treatment to Southeast Asia through our valued partnership with Cosmo Pharmaceuticals N.V. 🌏 Winlevi® is the first new topical acne treatment in over 40 years, and what sets it apart is its unique mechanism of action. The cream contains clascoterone, the first topical androgen receptor inhibitor available commercially. It directly targets androgen receptors in sebaceous glands without systemic anti-androgen effects, making it a safe choice for both males and females aged 12 and above.
This launch marks the start of a broader regional rollout across 10 SEA countries (Malaysia, Singapore, Indonesia, Philippines, Vietnam, Thailand, Brunei, Cambodia, Laos and Myanmar).
“Acne is a serious medical challenge that can have profound impacts on self esteem, social interactions and quality of life,” shares Lim See Wah, Chairman and CEO of Hyphens Pharma. “By expanding access to Winlevi®, we aim to support doctors in their practice and empower patients to manage acne with greater confidence, improving their quality of life.”
With millions worldwide living with acne, we’re heartened to be part of this new chapter in dermatology. 🔗Read more: https://www.hyphensgroup.com/?p=2312&preview=truehttps://www.hyphensgroup.com/?p=2312&preview=true